When was PAhR Therapeutics founded?

PAhR Therapeutics was founded in 2025 and raised its 1st funding round within a year of its incorporation.

Where is PAhR Therapeutics located?

PAhR Therapeutics is headquartered in Boston, United States.

Is PAhR Therapeutics a funded company?

PAhR Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Feb 27, 2025.

When was the latest funding round of PAhR Therapeutics?

PAhR Therapeutics' latest funding was a $***** Seed round on Feb 27, 2025, with participation from 3 investors. Its primary sector is Pulmonology. In United States, the Pulmonology sector has seen $938M in funding in 2026 to date.

Where does PAhR Therapeutics rank among its competitors?

PAhR Therapeutics ranks 9th amongst 22 active competitors, of which 4 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Tenax Therapeutics, which secured $25M in Mar, 2025.

Who are the top competitors of PAhR Therapeutics?

PAhR Therapeutics' top competitors include Actelion, Gossamer Bio and Aerovate Therapeutics. Among them, Tenax Therapeutics secured the most recent funding round in March, 2025.

PAhR Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of novel mechanisms for the treatment of pulmonary arterial hypertension. The company focuses on clinical-stage development of treatments for this specific condition. It aims to address unmet needs through innovative approaches.

Website: www.pahrtx.com/
Email ID: *****@pahrtx.com

Key Metrics

Founded Year

2025

Location

Boston, United States

Stage

Seed

Total Funding

$14M in 1 round

Latest Funding Round

Seed, Feb 27, 2025, $*****

Investors

RA Capital Management & 2 more

Ranked

9^th among 22 active competitors

Similar Companies

Actelion & 23 more

View PAhR Therapeutics' full profile

PAhR Therapeutics has raised a total funding of $14M over 1 round. Its latest funding round was a Seed round on Feb 27, 2025 for $*****. 3 investors participated in its latest round. PAhR Therapeutics has 3 institutional investors.

Here is the list of recent funding rounds of PAhR Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 27, 2025	7519780	Seed	7943994	7231946	9880952	4468339

Access funding benchmarks and valuations. Sign up today!

View details of PAhR Therapeutics's funding rounds and investors

The founders of PAhR Therapeutics are Ryotaro Asano and Makoto Okazawa.

Here are the details of PAhR Therapeutics' key team members:

Ryotaro Asano: Co-Founder of PAhR Therapeutics.
Makoto Okazawa: Co-Founder of PAhR Therapeutics.

View details of PAhR Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PAhR Therapeutics include Actelion, Gossamer Bio and Aerovate Therapeutics. Here is the list of Top 10 competitors of PAhR Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Actelion 1997, Allschwil (Switzerland), Acquired	Discovery, development, and commercialization of innovative treatments for orphan diseases	$46M	Atlas Venture, NeoMed & 11 others	63/100
2nd	Gossamer Bio 2017, San Diego (United States), Public	Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer	$330M	Arch Venture Partners, Omega Funds & 15 others	57/100
3rd	Aerovate Therapeutics 2018, Boston (United States), Public	Developer of therapeutic solutions for pulmonary arterial hypertension	$75.8M	Sofinnova Investments, Atlas Venture & 1 others	54/100
4th	Tenax Therapeutics 1967, Morrisville (United States), Public	Developer of therapeutics to address cardiovascular and pulmonary diseases	-	RTW Investments, Westwicke & 1 others	52/100
5th	Corsair Phama 2014, San Francisco (United States), Series B	Developer of drugs for the treatemnt of cardiac diseases	$23M	New Rhein, Primavera & 3 others	51/100
6th	Vivus 1991, Mountain View (United States), Public	Developer of therapeutic solutions for obesity and sexual health	-	Colt Ventures, Athyrium Capital Management ... & 9 others	47/100
7th	CoTherix 2000, San Francisco (United States), Acquired	Inhaled therapeutics for the treatment of cardiopulmonary diseases.	$55M	Frazier Life Sciences, Sofinnova Partners ... & 7 others	42/100
8th	tiakis BIOTECH 2000, Kiel (Germany), Series A	Developer of anti-inflammatory and tissue-protective drugs	-	Elevat3 Capital	39/100
9th	PAhR Therapeutics 2025, Boston (United States), Seed	Developer of novel mechanisms for the treatment of pulmonary arterial hypertension	$14M	RA Capital Management, UTEC & 1 others	33/100
10th	Apaxen 2018, Charleroi (Belgium), Series A	Developer of small molecules for treating pulmonary diseases	$3.64M	Theodorus, India Innovation Fund & 1 others	32/100